Future Market Insights

Hepatitis - B Therapeutics Market: 10-Year Market Forecast and Trends Analysis Research Report

Future Market Insights has announced the addition of the “Hepatitis - B Therapeutics Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering.


Valley Cottage, NY -- (SBWIRE) -- 03/17/2016 -- Hepatitis is a serious and common infectious disease which causes inflammation of liver, and can be caused by variety of different viruses such as A, B, C, D and E. Jaundice is a characteristic feature of liver disease. Hepatitis-B is a contagious liver disease which is results from infection with the Hepatitis-B virus (HBV), which is containing a partially double stranded and circular DNA. The virus interfers with hepatocytes, the liver became inflamed. HBV is transmitted through parenteral contact through body fluids, blood, and sexual intercourse. HBV does not able to cross skin or mucous membrane. People with Acquired Immuno Deficiency Syndrome (AIDS), Lymph proliferative disease, and people who are treated with Immuno suppressive drugs and hemodialysis patients are easily develops infection with Hepatitis-B Virus. There are two types of HBV infection Acute and Chronic. Acute Hepatitis B is initial six months of infected with HBV. After certain treatment also the infection remains in human body and leads to a "chronic hepatitis". There is no treatment for acute hepatitis B.

Hepatitis - B Therapeutics Market: Drivers and restraints

Global Hepatitis - B Therapeutics market can be driven by following drivers, According to the World Health Organization (WHO), Chronic HBV infection occurs majority of the infants, increasing prevalence of Hepatitis-B virus is major driver of the market. The prevalence rate of hepatitis B is increasing gradually, thus propels the Hepatitis B therapeutics market over the forecast period. There are less number of antibiotics are available in the market only antivirals are effectively fight with the HBV. Treatment and medications are highly expensive. These are major bottlenecks for Hepatitis B therapeutics Market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1224

Hepatitis - B Therapeutics Market: Segmentation

Global Hepatitis - B Therapeutics Market can be segmented as following types

Global Hepatitis - B Therapeutics market by Products:

By Product
Hepatitis B vaccine
Anti-Viral Drugs

By Distribution Channel
Hospitals Pharmacies
Pharmacies and Drug Stores

Hepatitis - B Therapeutics Market: Overview

Increasing the demand for advanced technological treatments and novel drug products to treat various rare diseases are provides a robust market growth. According Centers for Disease Prevention and Control (CDC), Approximately 1.4 Million patients in the United States are chronically infected with Hepatitis B Virus and the prevalence of hepatitis B virus is high European region followed by United States. The Hepatitis B vaccination and advanced treatment methods to treat Hepatitis B Virus propels Hepatitis - B Therapeutics market over the forecast period.

Hepatitis - B Therapeutics Market: Region-Wise Outlook

Depending upon the geographic regions Hepatitis - B Therapeutics market is segmented into seven key regions: Those are North America, Latin America, and Western Europe, Eastern Europe, and Asia pacific excluding japan, Middle East and Africa (MEA), Japan.

Download TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1224

North America dominating the global Hepatitis - B Therapeutics market followed by Europe. Increasing awareness among the people towards the use of novel products and technologies to treat the HBV providing lucrative market. Asian Pacific region market is considered to rapidly evolving healthcare infrastructure and research and development, this region is anticipating providing a robust growth of global Hepatitis - B Therapeutics market over the forecast period.

Hepatitis - B Therapeutics Market: Key players

Some of the key players in Market are GlaxoSmithKline, plc. Bristol-Myers Squibb, Hoffmann- La Roche, Novartis AG, Merck and Co.